Divya Birudaraju
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Divya Birudaraju has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Matthew Jay Budoff
Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California, USA
7 shared publications - Lavanya Cherukuri
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center, Torrance, CA, USA
6 shared publications - Ahmed Ghanem
Cardiology Department, The Lundquist Institute, Torrance, USA
3 shared publications - April Kinninger
The Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center, 1124 W Carson St, Torrance, CA 90502, USA
3 shared publications - Sajad Hamal
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center, Torrance, California, USA
3 shared publications - Suraj Dahal
Lundquist Institute, Harbor-UCLA Medical Center, Torrance, CA, USA
3 shared publications
Latest Publications
- 12 August 2021
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 19 (9) , 787-800
Current methods to assess mitral annular calcification and its risk factors
Mitral annulus calcification (MAC) is a chronic, non-inflammatory, degenerative mechanism of the fibrous base of the mitral valve. While MAC was originally thought to be an age-related degenerative...
- 12 August 2021
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 19 (9) , 787-800
Current methods to assess mitral annular calcification and its risk factors
Mitral annulus calcification (MAC) is a chronic, non-inflammatory, degenerative mechanism of the fibrous base of the mitral valve. While MAC was originally thought to be an age-related degenerative...
- Open Access
- 23 April 2021
- Published by Radcliffe Medical Media Ltd in US Cardiology Review
- Vol. 15
Novel Non-invasive Fractional Flow Reserve from Coronary CT Angiography to Determine Ischemic Coronary Stenosis
Coronary artery disease (CAD) patients may have an obstructive disease on invasive coronary angiography, but few of these patients have had flow-limiting obstructive disease diagnosed on invasive fractional flow reserve (FFR). FFR is infrequently performed because of its cost- and time-effectiveness. Advancement in non-invasive imaging has enabled FFR to be derived non-invasively using coronary CT angiography (CCTA), without the need for induction of hyperemia or modification of the standard CCTA acquisition protocol. FFR derived from CCTA (FFRCT) has been shown to have excellent correlation with invasive FFR, and remains an effective diagnostic tool in the presence of reduced signal-to-noise ratio, coronary calcification and motion artifact. The utility of FFRCT has also helped to deepen our understanding of hemodynamically significant CAD. Hence, there is now interest in exploring the possible interplay between these mechanistic forces and their effect on the development of coronary plaque and the vulnerability of these plaques.
- 23 April 2021
- Published by Radcliffe Medical Media Ltd in US Cardiology Review
- Vol. 15
Open AccessNovel Non-invasive Fractional Flow Reserve from Coronary CT Angiography to Determine Ischemic Coronary Stenosis
Coronary artery disease (CAD) patients may have an obstructive disease on invasive coronary angiography, but few of these patients have had flow-limiting obstructive disease diagnosed on invasive fractional flow reserve (FFR). FFR is infrequently performed because of its cost- and time-effectiveness. Advancement in non-invasive imaging has enabled FFR to be derived non-invasively using coronary CT angiography (CCTA), without the need for induction of hyperemia or modification of the standard CCTA acquisition protocol. FFR derived from CCTA (FFRCT) has been shown to have excellent correlation with invasive FFR, and remains an effective diagnostic tool in the presence of reduced signal-to-noise ratio, coronary calcification and motion artifact. The utility of FFRCT has also helped to deepen our understanding of hemodynamically significant CAD. Hence, there is now interest in exploring the possible interplay between these mechanistic forces and their effect on the development of coronary plaque and the vulnerability of these plaques.
- 1 March 2021
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 35 (3) , 107840
Prevalence of normal coronary arteries by coronary computed tomography angiography (CCTA) in patients with type 2 diabetes mellitus from Semaglutide Treatment on Coronary Plaque Progression (STOP) trial
- 1 March 2021
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 35 (3) , 107840
Prevalence of normal coronary arteries by coronary computed tomography angiography (CCTA) in patients with type 2 diabetes mellitus from Semaglutide Treatment on Coronary Plaque Progression (STOP) trial
- 1 November 2020
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 14 (6) , 490-494
Feasibility of measuring pericoronary fat from precontrast scans: Effect of iodinated contrast on pericoronary fat attenuation
- 1 November 2020
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 14 (6) , 490-494
Feasibility of measuring pericoronary fat from precontrast scans: Effect of iodinated contrast on pericoronary fat attenuation
- 1 July 2020
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 14 (3) , S40
Association Of Serum Fibrinogen Levels With Thoracic Fat Volumes By Cardiac CT: EVAPORATE (Effect Of Vascepa On Improving Coronary Atherosclerosis In People With High Triglycerides (TGL) Taking Statin Therapy) Trial
- 1 July 2020
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 14 (3) , S40
Association Of Serum Fibrinogen Levels With Thoracic Fat Volumes By Cardiac CT: EVAPORATE (Effect Of Vascepa On Improving Coronary Atherosclerosis In People With High Triglycerides (TGL) Taking Statin Therapy) Trial
- 1 July 2020
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 14 (3) , S38-S39
Lower Utilization Of Contrast Media And Beta-blocker In 256-detector Ge Revolution Ct Scanner: The Converge Registry
- 1 July 2020
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 14 (3) , S38-S39
Lower Utilization Of Contrast Media And Beta-blocker In 256-detector Ge Revolution Ct Scanner: The Converge Registry
- Open Access
- 30 November 2019
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (7) , 2142-2149
Biomarkers and Noncalcified Coronary Artery Plaque Progression in Older Men Treated With Testosterone
Objective Recent results from the Cardiovascular (CV) Trial of the Testosterone(T) Trials showed that T treatment of older men with low T was associated with greater progression of non-calcified plaque (NCP). We evaluated the effect of anthropometric measures and cardiovascular biomarkers on plaque progression in individuals in the T Trial. Methods The CV part of the trial included 170 men aged 65 years or older with low T. Participants received T gel or placebo gel for 12 months. The primary outcome was change in NCP volume from baseline to 12 months, as determined by coronary computed tomography angiography (CCTA). We assayed several markers of CV risk and analyzed each marker individually in a model as predictive variables and change in NCP as the dependent variable. RESULTS Of 170 enrollees, 138 (73 T, 65 placebo) completed the study and were available for the primary analysis. Of 10 markers evaluated, none showed a significant association with the change in NCP volume, but a significant interaction between treatment assignment and waist-hip ratio p-0.0014) indicated that this variable impacted the testosterone effect on non-calcified plaque volume. The statistical model indicated that for every 0.1 change in the waist-hip ratio, the T-induced 12-month change in non-calcified plaque volume increased by 26.96 mm3 (95% confidence interval 7.72, 46.20). Conclusion Among older men with low T treated for one year, greater waist-hip ratio was associated with greater NCP progression, as measured by CCTA. Other biomarkers and anthropometric measures did not show statistically significant association with plaque progression.
- 30 November 2019
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (7) , 2142-2149
Open AccessBiomarkers and Noncalcified Coronary Artery Plaque Progression in Older Men Treated With Testosterone
Objective Recent results from the Cardiovascular (CV) Trial of the Testosterone(T) Trials showed that T treatment of older men with low T was associated with greater progression of non-calcified plaque (NCP). We evaluated the effect of anthropometric measures and cardiovascular biomarkers on plaque progression in individuals in the T Trial. Methods The CV part of the trial included 170 men aged 65 years or older with low T. Participants received T gel or placebo gel for 12 months. The primary outcome was change in NCP volume from baseline to 12 months, as determined by coronary computed tomography angiography (CCTA). We assayed several markers of CV risk and analyzed each marker individually in a model as predictive variables and change in NCP as the dependent variable. RESULTS Of 170 enrollees, 138 (73 T, 65 placebo) completed the study and were available for the primary analysis. Of 10 markers evaluated, none showed a significant association with the change in NCP volume, but a significant interaction between treatment assignment and waist-hip ratio p-0.0014) indicated that this variable impacted the testosterone effect on non-calcified plaque volume. The statistical model indicated that for every 0.1 change in the waist-hip ratio, the T-induced 12-month change in non-calcified plaque volume increased by 26.96 mm3 (95% confidence interval 7.72, 46.20). Conclusion Among older men with low T treated for one year, greater waist-hip ratio was associated with greater NCP progression, as measured by CCTA. Other biomarkers and anthropometric measures did not show statistically significant association with plaque progression.